Siraj Ahmed, MD
Pulmonary Disease · Manteca, CANPI 1265513121
Payments from drug & device makers
Across 228 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$769
- GSK$708
- Boehringer Ingelheim$632
- Itamar Medical Inc$381
- Mylan Specialty L.p.$379
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,78495%
- Education$2785%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $1,048 |
| Regeneron Healthcare Solutions, Inc. | 22 | $769 |
| GSK | 42 | $708 |
| Boehringer Ingelheim | 27 | $632 |
| Itamar Medical Inc | 3 | $381 |
| Mylan Specialty L.p. | 17 | $379 |
| Actelion Pharmaceuticals US, Inc. | 9 | $272 |
| Grifols USA, LLC | 9 | $248 |
| Verona Pharma, Inc. | 8 | $220 |
| Sanofi | 5 | $218 |
| Amgen | 8 | $152 |
| Johnson & Johnson | 9 | $144 |
| Bayer | 3 | $144 |
| Viatris Specialty LLC | 5 | $115 |
| Teva Pharmaceuticals USA, Inc. | 1 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Lilly USA, LLC | 3 | $65 |
| Insmed, Inc. | 2 | $59 |
| Resmed Corp | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Gilead | 1 | $27 |
| Fisher & Paykel Healthcare Inc | 1 | $27 |
| Edwards Lifesciences | 1 | $26 |
| Vapotherm Inc | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Boston Scientific | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$491
- WatchPATONE$356
- Adempas$117
- CINQAIR$114
- Ohtuvayre$108
How this compares
$6,063 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 268 | $213,487 |
| OfevNintedanib Esylate | 12 | $155,439 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $87,979 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $42,765 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $15,695 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $14,988 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 53 | $14,180 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 30 | $13,912 |
| Spiriva RespimatTiotropium Bromide | 20 | $13,723 |
| BreynaBudesonide/Formoterol Fumarate | 67 | $13,059 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 341 | $9,207 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,901 |
| Fluticasone Propionate HfaFluticasone Propionate | 21 | $4,882 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $2,684 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $1,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $708 | $237,083315 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat | $632 | $183,07362 claims |
| Grifols USA, LLCProlastin C | $248 | $87,97912 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,048 | $57,753106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Manteca
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.